Breaking news

Global Airline Industry Set To Hit $1 Trillion By 2025 Despite Supply Chain Turbulence

The global airline industry is on track to achieve record revenues of $1 trillion by 2025, according to the International Air Transport Association (IATA). While passenger numbers continue to rise, the sector faces persistent challenges, including aircraft supply chain disruptions and operational delays.

Record Revenue and Profit Growth

IATA projects a net profit of $36.6 billion for the airline sector in 2025, a rise from the $31.5 billion expected in 2024. Passenger traffic remains strong, with a record 5.2 billion passengers travelling in 2024. Although growth in 2025 is forecasted to be more moderate, it will still contribute to a sustained recovery following the COVID-19-induced collapse of 2020, which saw industry losses of $140 billion.

Lower fuel prices are providing some relief for airlines. Brent crude oil prices have declined by 20% over the past year, easing operating costs. The outlook is further supported by expectations of looser fiscal policies worldwide, which could bolster consumer purchasing power and drive global economic growth.

Supply Chain Disruptions Hamper Expansion

Despite positive financial projections, airlines face significant operational challenges. Strikes and technical issues at major aircraft manufacturers Boeing and Airbus have delayed deliveries of new, more fuel-efficient planes. These delays are problematic for airlines seeking to modernise their fleets and reduce fuel costs.

Boeing’s production of the 737 MAX aircraft was disrupted after a seven-week strike involving more than 70,000 employees. Following a new labour agreement that includes a 38% wage increase over four years, production has resumed. However, the backlog of more than 4,000 pending orders poses a logistical hurdle for Boeing as it seeks to meet growing airline demand.

A Look Ahead

As the airline industry edges closer to the $1 trillion revenue milestone, it must navigate both opportunities and obstacles. Rising passenger numbers and easing fuel costs are key growth drivers. However, production delays at Boeing and Airbus highlight the fragile nature of the sector’s supply chain.

The coming years will be defined by how well the industry adapts to these challenges. Airlines reliant on timely fleet upgrades may face operational setbacks, but the overall outlook remains positive. With strong global demand, increased profits, and declining fuel costs, the sector is poised for continued growth—though not without turbulence along the way.

Medochemie And Theramir Announce Strategic Investment Agreement To Advance Biotech Manufacturing In Cyprus

Pharmaceutical manufacturer Medochemie and biotechnology company Theramir, both Cyprus-based, have announced a strategic investment agreement and collaboration aimed at developing next-generation biological therapies and expanding manufacturing capabilities in Cyprus.

The agreement, announced on 2 September 2026, brings together Medochemie’s experience in pharmaceutical manufacturing and Theramir’s biotechnology research. The companies said the collaboration would support advanced pharmaceutical manufacturing in Cyprus and south-eastern Europe.

What The Partnership Covers

Medochemie’s contribution will include its expertise in manufacturing sterile therapeutic products and its access to international markets.

Theramir develops technologies based on extracellular vesicles and microRNAs. Its work includes using stem-cell-derived extracellular vesicles to deliver microRNAs, small, non-coding RNA molecules that regulate genes and biological pathways associated with cancer growth and metastasis.

Under the agreement, the companies will jointly support the development of “Good Manufacturing Practice” capabilities for next-generation biological therapies. The partnership is also intended to help move these therapies towards clinical development.

A Wider Role For Cyprus

The collaboration will also support Theramir’s wider research programme. According to the companies, it is intended to strengthen Cyprus’s biotechnology infrastructure and expand local capacity in next-generation biomanufacturing.

They present the agreement as a step towards giving Cyprus a larger role in biotechnology and advanced pharmaceutical manufacturing for south-eastern Europe and international markets.

Aretilaw firm
eCredo
Uol
The Future Forbes Realty Global Properties

Become a Speaker

Become a Speaker

Become a Partner

Subscribe for our weekly newsletter